With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.
GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
Hosted on MSN54m
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage UniverseValuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback